Patents by Inventor Yao-Ming Huang
Yao-Ming Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018239Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: ApplicationFiled: August 24, 2023Publication date: January 18, 2024Applicant: 23andMe, Inc.Inventors: Yu CHEN, Jilean Beth FENAUX, Germaine FUH-KELLY, Yao-Ming HUANG, Wei-Jen CHUNG, Erik KARRER, Cecilia LAY, Steven J. PITTS, Louise SCHARF
-
Patent number: 11787861Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignee: 23andMe, Inc.Inventors: Yu Chen, Jilean Beth Fenaux, Germaine Fuh-Kelly, Yao-Ming Huang, Wei-Jen Chung, Erik Edward Karrer, Cecilia Lay, Steven J. Pitts, Louise Scharf
-
Publication number: 20230235040Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: ApplicationFiled: June 21, 2021Publication date: July 27, 2023Inventors: Thomas Huber, Vicente Marco Garcia Gonzalez, Bernat Vidal Juan, Germaine Fuh-Kelly, Yao-ming Huang
-
Publication number: 20230183343Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: ApplicationFiled: November 18, 2022Publication date: June 15, 2023Applicant: 23andMe, Inc.Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
-
Patent number: 11555073Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: GrantFiled: December 18, 2019Date of Patent: January 17, 2023Assignee: 23andMe, Inc.Inventors: Yu Chen, Chingwei Vivian Lee, Germaine Fuh-Kelly, Zuoan Yi, Yao-ming Huang, Valentine Yeung, Krista Maureen McCutcheon, Samuel Nalle, Augusta Eleanor Broughton, Louise Scharf, Navneet Singh, Tina Thai, Shouhua Xiao
-
Publication number: 20220213431Abstract: The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.Type: ApplicationFiled: August 13, 2021Publication date: July 7, 2022Applicants: Biogen MA Inc., Samsung BioepisInventors: William C. Yang, Yao-Ming Huang, Marty Sinacore, Thomas Ryll, Jiuyi Lu, Jaesun Lee, Kyngju Lee, Hyoung Taek Lim, Eunchong Yang
-
Publication number: 20220106395Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: ApplicationFiled: September 27, 2021Publication date: April 7, 2022Applicant: 23andMe, Inc.Inventors: Davide Foletti, Erik Karrer, Germaine Fuh-KELLY, Kristie Ibarra, Quan Zheng, Yao-ming Huang, Lindsay Deis, Christine Wolak, Dominic Samuel Berns
-
Publication number: 20210371521Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.Type: ApplicationFiled: May 28, 2021Publication date: December 2, 2021Applicant: 23andMe, Inc.Inventors: Yu CHEN, Jilean Beth FENAUX, Germaine FUH-KELLY, Yao-Ming HUANG, Wei-Jen CHUNG, Erik Edward KARRER, Cecilia LAY, Steven J. PITTS, Louise SCHARF
-
Patent number: 11168140Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: GrantFiled: August 15, 2019Date of Patent: November 9, 2021Assignee: 23andMe, Inc.Inventors: Davide Foletti, Erik Karrer, Germaine Fuh-Kelly, Kristie Ibarra, Quan Zheng, Yao-ming Huang, Lindsay Deis, Christine Wolak, Dominic Samuel Berns
-
Patent number: 11124760Abstract: The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.Type: GrantFiled: March 24, 2015Date of Patent: September 21, 2021Assignees: Biogen MA Inc., Samsung BioepisInventors: William Yang, Yao-Ming Huang, Marty Sinacore, Thomas Ryll, Jiuyi Lu, Jaesun Lee, Kyngju Lee, Hyoung Taek Lim, Eunchong Yang
-
Publication number: 20200199227Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Applicant: 23andMe, Inc.Inventors: Yu CHEN, Chingwei Vivian LEE, Germaine FUH-KELLY, Zuoan YI, Yao-ming HUANG, Valentine YEUNG, Krista Maureen MCCUTCHEON, Samuel NALLE, Augusta Eleanor BROUGHTON, Louise SCHARF, Navneet SINGH, Tina THAI, Shouhua XIAO
-
Patent number: 10676772Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: GrantFiled: April 16, 2018Date of Patent: June 9, 2020Assignees: Biogen MA Inc., Samsung BioepisInventors: William C. Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Liu Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
-
Publication number: 20200095328Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human interleukin-1 receptor accessory protein (hu-IL1RAP) and fully block the IL-1, IL-33, and IL-36 intracellular signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.Type: ApplicationFiled: August 15, 2019Publication date: March 26, 2020Applicant: 23andMe, Inc.Inventors: Davide Foletti, Erik Karrer, Germaine Fuh, Kristie Ibarra, Quan Zheng, Yao-ming Huang, Lindsay Deis, Christine Wolak, Dominic Samuel Berns
-
Publication number: 20190085369Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: ApplicationFiled: April 16, 2018Publication date: March 21, 2019Applicants: Biogen MA Inc., Samsung BioepisInventors: William C. Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Liu Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
-
Patent number: 9944968Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: GrantFiled: January 19, 2016Date of Patent: April 17, 2018Assignees: Biogen MA Inc., Samsung BioepisInventors: William Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
-
Publication number: 20170327786Abstract: The present invention pertains to a cell culture medium comprising hypotaurine, GABA, and/or beta-alanine or the combination of choline and hypotaurine, GABA, and/or beta-alanine as media supplements which is shown to control viability, growth, and waste byproduct accumulation. The present invention further pertains to a method of producing a polypeptide of interest in a large scale cell culture containing hypotaurine, GABA, and/or beta-alanine or the combination of choline and hypotaurine, GABA, and/or beta-alanine.Type: ApplicationFiled: October 30, 2015Publication date: November 16, 2017Applicant: Biogen MA Inc.Inventors: Yao-Ming HUANG, William C. YANG, Alan GILBERT, Kyle MCELEARNEY
-
Publication number: 20170175075Abstract: The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.Type: ApplicationFiled: March 24, 2015Publication date: June 22, 2017Applicants: Biogen MA Inc., Samsung BioepisInventors: William YANG, Yao-Ming HUANG, Marty SINACORE, Thomas RYLL, Jiuyi LU, Jaesun LEE, Kyngju LEE, Hyoung Taek LIM, Eunchong YANG
-
Publication number: 20160304928Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: ApplicationFiled: January 19, 2016Publication date: October 20, 2016Applicant: Biogen MA Inc.Inventors: William YANG, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Tsang, Thomas Ryll
-
Publication number: 20160289633Abstract: Methods of improving the efficiency of production of a protein product of interest in mammalian cell culture are presented. In particular, the methods result in an increase in the quantity of a protein product produced, or decreases protein product production time in a manufacturing-scale bioreactor cell culture. The disclosed methods comprise: (a) culturing the N-1 bioreactor culture to high viable cell densities; and (b) seeding the production bioreactor culture at high viable cell seeding densities.Type: ApplicationFiled: December 19, 2014Publication date: October 6, 2016Applicant: Biogen MA Inc.Inventors: William C. YANG, Jiuyi LU, Yao-Ming HUANG, Hang YUAN, Rashmi KSHIRSAGAR, Thomas RYLL
-
Publication number: 20160237399Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.Type: ApplicationFiled: February 18, 2015Publication date: August 18, 2016Applicant: Biogen MA Inc.Inventors: William YANG, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Tsang, Thomas Ryll